Rameen Beroukhim, MD, PhD
Assistant Professor, Department of Medicine, Harvard Medical School
Attending Physician, Medicine, Brigham And Women's Hospital
Associate Member, Cancer Program, Broad Institute of MIT and Harvard
Assistant Professor, Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute
DF/HCC Program AffiliationNeuro-Oncology
Lab WebsiteBeroukhim Laboratory
Research AbstractThe Beroukhim laboratory focuses on understanding the somatic genetics of cancer, primarily in identifying alterations in chromosomal structure (including copy-number gains and losses and loss of heterozygosity) that contribute to tumor growth, and characterizing the biological effects of these alterations. The aims of these experiments are to understand the biological basis of the various cancer subtypes to guide development of therapeutics, and to develop prognostic and predictive markers to guide the application of those therapeutics.
Much of our effort focuses on developing computational methods with general applicability to the study of the somatic genetics of cancer. An example is the Genomic Identification of Significant Targets In Cancer (GISTIC) algorithm, a statistical technique that distinguishes chromosomal alterations that are likely to drive tumorigenesis from alterations that may result from random chance alone. We and our collaborators have used this approach to identify novel oncogenes in lung adenocarcinoma (NKX2-1), lung and esophageal squamous cell cancers (SOX2), and colon cancer (CDK8). We have also used the technique to identify prognostic and predictive indicators in a variety of cancers. Recently, we have developed these methods to perform unified analyses across over 3000 cancers of several dozen types, in which we identified two new amplified oncogenes (MCL1 and BCL2L1) and an overarching unity to cancer genomes. We are currently extending these approaches to additional cancer types and higher quality, integrated datasets.